Considering the effects of single gene expression on patient survival, these data suggest that increased expression of either CD44 or SLC16A1 is a candidate prognostic marker for pancreatic cancer patients, and that targeting CD44 and MCT1 together is required for the proper treatment of aggressive pancreatic cancers. The gene discussed is SLC16A1; the disease is familial pancreatic carcinoma.